Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> Risk assessment for CVD, diabetes includes: hx, exam/BP, lab (including FBG, fasting lipid panel). Waist circ cutpoints indicate ↑ cardiometabolic risk [E]: women: >88 cm (>35 in); men: >102 cm (>40 in). If BMI >35, not necessary to measure waist circ.<br><br>
<sup>2</sup> ↑ BMI assoc w/ ↑ risk of CVD/Type 2 DM/all-cause mortality [S/B].
<br><br>
<sup>3</sup> If CV risks (↑ BP, hyperlipidemia, hyperglycemia): counsel that lifestyle changes producing even modest, sustained wt ↓ of 3-5% produce clinically meaningful health benefits [S/A]. Sustained 3-5% wt ↓ is likely to meaningfully reduce TGs, BG, HbA1C, and Type 2 DM risk. Greater wt ↓ will ↓ BP, improve cholesterol, ↓ need for meds to control BP, glucose, and lipids, and further ↓ TGs, BG [S/A].
<br><br>
<sup>4</sup> Waist circ cutpoints indicate ↑ cardiometabolic risk [E]: women: >88 cm (>35 in); men: >102 cm (>40 in).
<sup>2</sup> ↑ BMI assoc w/ ↑ risk of CVD/Type 2 DM/all-cause mortality [S/B].
<br><br>
<sup>3</sup> If CV risks (↑ BP, hyperlipidemia, hyperglycemia): counsel that lifestyle changes producing even modest, sustained wt ↓ of 3-5% produce clinically meaningful health benefits [S/A]. Sustained 3-5% wt ↓ is likely to meaningfully reduce TGs, BG, HbA1C, and Type 2 DM risk. Greater wt ↓ will ↓ BP, improve cholesterol, ↓ need for meds to control BP, glucose, and lipids, and further ↓ TGs, BG [S/A].
<br><br>
<sup>4</sup> Waist circ cutpoints indicate ↑ cardiometabolic risk [E]: women: >88 cm (>35 in); men: >102 cm (>40 in).
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
Obese. Identify barriers, address CVD risk factors<sup>1</sup> and obesity-related comorbidities